Lyra Therapeutics (LYRA) Competitors $0.09 0.00 (-0.22%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LYRA vs. CLGN, MDAI, COCH, PYPD, DRIO, PTHL, NXL, NEPH, RVP, and NXGLShould you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include CollPlant Biotechnologies (CLGN), Spectral AI (MDAI), Envoy Medical (COCH), PolyPid (PYPD), DarioHealth (DRIO), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), Nexalin Technology (NXL), Nephros (NEPH), Retractable Technologies (RVP), and NEXGEL (NXGL). These companies are all part of the "medical equipment" industry. Lyra Therapeutics vs. CollPlant Biotechnologies Spectral AI Envoy Medical PolyPid DarioHealth Pheton Holdings Ltd Class A Ordinary Shares Nexalin Technology Nephros Retractable Technologies NEXGEL Lyra Therapeutics (NASDAQ:LYRA) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership. Do institutionals and insiders hold more shares of LYRA or CLGN? 95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 4.7% of Lyra Therapeutics shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor LYRA or CLGN? In the previous week, Lyra Therapeutics and Lyra Therapeutics both had 2 articles in the media. Lyra Therapeutics' average media sentiment score of 0.94 equaled CollPlant Biotechnologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer LYRA or CLGN? CollPlant Biotechnologies received 117 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 60.00% of users gave CollPlant Biotechnologies an outperform vote while only 58.54% of users gave Lyra Therapeutics an outperform vote. CompanyUnderperformOutperformLyra TherapeuticsOutperform Votes2458.54% Underperform Votes1741.46% CollPlant BiotechnologiesOutperform Votes14160.00% Underperform Votes9440.00% Which has better valuation & earnings, LYRA or CLGN? CollPlant Biotechnologies has lower revenue, but higher earnings than Lyra Therapeutics. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyra Therapeutics$1.53M3.94-$62.68M-$1.43-0.06CollPlant Biotechnologies$515K55.61-$7.02M-$1.46-1.71 Do analysts recommend LYRA or CLGN? Lyra Therapeutics presently has a consensus target price of $1.25, suggesting a potential upside of 1,263.14%. CollPlant Biotechnologies has a consensus target price of $12.50, suggesting a potential upside of 400.00%. Given Lyra Therapeutics' higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than CollPlant Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00CollPlant Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is LYRA or CLGN more profitable? CollPlant Biotechnologies has a net margin of -2,680.00% compared to Lyra Therapeutics' net margin of -6,635.76%. CollPlant Biotechnologies' return on equity of -77.05% beat Lyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lyra Therapeutics-6,635.76% -125.07% -59.74% CollPlant Biotechnologies -2,680.00%-77.05%-61.43% Which has more risk & volatility, LYRA or CLGN? Lyra Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. SummaryCollPlant Biotechnologies beats Lyra Therapeutics on 11 of the 17 factors compared between the two stocks. Remove Ads Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYRA vs. The Competition Export to ExcelMetricLyra TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.04M$4.10B$5.33B$7.45BDividend YieldN/A39.51%5.11%4.32%P/E Ratio-0.0627.7421.7417.79Price / Sales3.9449.97371.9593.87Price / CashN/A51.0838.1534.64Price / Book0.065.806.403.98Net Income-$62.68M$67.09M$3.20B$247.46M7 Day PerformanceN/A0.08%2.19%1.15%1 Month PerformanceN/A-3.12%-9.07%-6.52%1 Year PerformanceN/A14.96%9.89%0.20% Lyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYRALyra Therapeutics2.6172 of 5 stars$0.09-0.2%$1.25+1,258.7%-98.3%$6.06M$1.53M-0.0650Negative NewsCLGNCollPlant Biotechnologies2.3614 of 5 stars$2.40-2.4%$12.50+420.8%-52.6%$27.49M$515,000.00-1.5670MDAISpectral AI2.4858 of 5 stars$1.18-2.5%$4.75+302.5%-37.7%$27.43M$27.26M-1.8283Short Interest ↑COCHEnvoy Medical1.8903 of 5 stars$1.28-10.2%$9.00+605.9%-78.4%$25.81M$225,000.00-0.9034Gap DownPYPDPolyPid2.9869 of 5 stars$2.41-4.0%$11.33+370.3%-40.0%$24.56MN/A-0.4880Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsDRIODarioHealth2.1161 of 5 stars$0.58+3.1%$1.50+159.7%-38.3%$24.01M$27.04M-0.61200News CoveragePTHLPheton Holdings Ltd Class A Ordinary SharesN/A$3.63+8.0%N/AN/A$23.89M$448,196.000.0011News CoveragePositive NewsNXLNexalin Technology3.157 of 5 stars$1.65-2.4%$5.00+203.0%-12.6%$21.95M$168,721.00-2.583Gap DownNEPHNephros2.1014 of 5 stars$1.95-4.4%$5.00+156.4%+0.2%$20.67M$14.16M-21.6730Positive NewsGap DownRVPRetractable TechnologiesN/A$0.68flatN/A-33.9%$20.36M$38.27M-1.26240Gap DownNXGLNEXGEL0.4822 of 5 stars$2.63+2.3%N/A+28.4%$20.13M$8.69M-4.5310Short Interest ↑Gap Down Remove Ads Related Companies and Tools Related Companies CLGN Competitors MDAI Competitors COCH Competitors PYPD Competitors DRIO Competitors PTHL Competitors NXL Competitors NEPH Competitors RVP Competitors NXGL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LYRA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
